Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Each group had six subjects receiving doses of IMT-002 between 350 mg and 1050 mg administered as a once-daily or twice-daily regimen over a two-week duration. Six people received placebo and were interspersed in the four groups.
Lead Product(s): Methyldopa
Therapeutic Area: Endocrinology Product Name: IMT-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2021
Details:
The study will compare IMT-002 vs placebo for safety, tolerability and pharmacokinetic profiles. IMT-002 has been developed as a selective HLA-DQ8 blocker based on extensive computational work, in vitro and in vivo characterization.
Lead Product(s): Methyldopa
Therapeutic Area: Endocrinology Product Name: IMT-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020